UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [64/67Cu]Cu-SARTATE

EJNMMI research, 2021-08, Vol.11 (1), p.75-75, Article 75

2021

Volltextzugriff (PDF)

SUVpeak Performance in Lung Cancer: Comparison to Average SUV from the 40 Hottest Voxels

The Journal of nuclear medicine (1978), 2016-01, Vol.57 (1), p.85-88

2016

Volltextzugriff (PDF)

Is Patlak y-intercept a relevant metrics?

European journal of nuclear medicine and molecular imaging, 2021-05, Vol.48 (5), p.1287-1290

2021

Volltextzugriff (PDF)

On Semiquantitative Methods for Assessing Vascular 18 F-FDG PET Activity in Large-Vessel Vasculitis

Journal of Nuclear Medicine, 2022-02, Vol.63 (2), p.325-326

2022

Volltextzugriff (PDF)

Specific and Nonspecific Uptake in Quantitative 89 Zr-Immuno-PET

Journal of Nuclear Medicine, 2021-10, Vol.62 (10), p.1484-1485

2021

Volltextzugriff (PDF)

Specific and Nonspecific Uptake in Quantitative 89Zr-Immuno-PET

The Journal of nuclear medicine (1978), 2021-10, Vol.62 (10), p.1484-1485

2021

Volltextzugriff (PDF)

Is There a Relevant Imaging Time for Optimal Quantitative 89 Zr-DFO-Daratumumab PET Imaging?

Radiology, 2021-06, Vol.299 (3), p.E285-E285

2021

Volltextzugriff (PDF)

Automated segmentation of TMTV in DLBCL patients: what about method measurement uncertainty?

Journal of Nuclear Medicine, 2021-03, Vol.62 (3), p.431-431

2021

Volltextzugriff (PDF)

Distribution Volume of 18F-BMS‐986192 in NSCLC Patients

The Journal of nuclear medicine (1978), 2021-01, Vol.62 (1), p.144-144

2021

Volltextzugriff (PDF)

Distribution Volume of 18 F-BMS-986192 in NSCLC Patients

Journal of Nuclear Medicine, 2021-01, Vol.62 (1), p.144-144

2021

Volltextzugriff (PDF)

11 C-(+)-PHNO Trapping Reversibility for Quantitative PET Imaging of β-Cell Mass in Patients with Type 1 Diabetes

Journal of Nuclear Medicine, 2020-11, Vol.61 (11), p.1692-1693

2020

Volltextzugriff (PDF)

SUVmax-V for Assessing Treatment Response in 18F-FDG PET Imaging of Patient-Derived Tumor Xenografts Involving Triple-Negative Breast Cancer

The Journal of nuclear medicine (1978), 2020-09, Vol.61 (9), p.1405-1409

2020

Volltextzugriff (PDF)

SUV max-V for Assessing Treatment Response in 18 F-FDG PET Imaging of Patient-Derived Tumor Xenografts Involving Triple-Negative Breast Cancer

Journal of Nuclear Medicine, 2020-09, Vol.61 (9), p.1405-1409

2020

Volltextzugriff (PDF)

Correction to: Is Patlak y-intercept a relevant metrics?

European journal of nuclear medicine and molecular imaging, 2021-05, Vol.48 (5), p.1694-1694

2021

Volltextzugriff (PDF)

64 Cu-/ 177 Lu-Cetuximab Theranostic Pair: May the Single 64 Cu-Cetuximab Diagnostic Scan Be Acquired at Any Time After Injection?

Cancer biotherapy & radiopharmaceuticals, 2023-02, Vol.38 (1), p.74-76

2023

Volltextzugriff (PDF)

Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging

The Journal of nuclear medicine (1978), 2020-04, Vol.61 (4), p.620-620

2020

Volltextzugriff (PDF)

Reversibility of 68 Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging

Journal of Nuclear Medicine, 2020-04, Vol.61 (4), p.620-620

2020

Volltextzugriff (PDF)

SUR for mediastinal metastatic lymph node status in non-small-cell lung cancer patients

European journal of nuclear medicine and molecular imaging, 2020-11, Vol.47 (12), p.2737-2738

2020

Volltextzugriff (PDF)

Estimation of Cumulative Activity of 177 Lu-Cetuximab from a Single Diagnostic 64 Cu-Cetuximab Scan

Cancer biotherapy & radiopharmaceuticals, 2022-06, Vol.37 (5), p.403-409

2022

Volltextzugriff (PDF)

Prognostic value of 18 F-FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

Haematologica (Roma), 2020-01, Vol.105 (1), p.e41-e41

2020

Volltextzugriff (PDF)

Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with 18 F-fluoride

Journal of Nuclear Medicine, 2019-04, Vol.60 (4), p.568-568

2019

Volltextzugriff (PDF)

Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with 18F-Fluoride

The Journal of nuclear medicine (1978), 2019-04, Vol.60 (4), p.568-568

2019

Volltextzugriff (PDF)

On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma

Journal of clinical oncology, 2017-03, Vol.35 (8), p.919-920

2017

Volltextzugriff (PDF)

6″- 18 F-Fluoromaltotriose PET Evaluation in Escherichia Coli -Induced Myositis: Is There Uptake Saturation in Control?

Journal of Nuclear Medicine, 2018-07, Vol.59 (7), p.1166-1166

2018

Volltextzugriff (PDF)

Could we avoid computing TMTV of DLBCL patients in routine practice?

European journal of nuclear medicine and molecular imaging, 2018-11, Vol.45 (12), p.2235-2237

2018

Volltextzugriff (PDF)

1 – 25 von 116

Menü

Weitere Dienste

Einstellungen

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [64/67Cu]Cu-SARTATE

SUVpeak Performance in Lung Cancer: Comparison to Average SUV from the 40 Hottest Voxels

Is Patlak y-intercept a relevant metrics?

On Semiquantitative Methods for Assessing Vascular 18 F-FDG PET Activity in Large-Vessel Vasculitis

Specific and Nonspecific Uptake in Quantitative 89 Zr-Immuno-PET

Specific and Nonspecific Uptake in Quantitative 89Zr-Immuno-PET

Is There a Relevant Imaging Time for Optimal Quantitative 89 Zr-DFO-Daratumumab PET Imaging?

Automated segmentation of TMTV in DLBCL patients: what about method measurement uncertainty?

Distribution Volume of 18F-BMS‐986192 in NSCLC Patients

Distribution Volume of 18 F-BMS-986192 in NSCLC Patients

11 C-(+)-PHNO Trapping Reversibility for Quantitative PET Imaging of β-Cell Mass in Patients with Type 1 Diabetes

SUVmax-V for Assessing Treatment Response in 18F-FDG PET Imaging of Patient-Derived Tumor Xenografts Involving Triple-Negative Breast Cancer

SUV max-V for Assessing Treatment Response in 18 F-FDG PET Imaging of Patient-Derived Tumor Xenografts Involving Triple-Negative Breast Cancer

Correction to: Is Patlak y-intercept a relevant metrics?

64 Cu-/ 177 Lu-Cetuximab Theranostic Pair: May the Single 64 Cu-Cetuximab Diagnostic Scan Be Acquired at Any Time After Injection?

Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging

Reversibility of 68 Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging

SUR for mediastinal metastatic lymph node status in non-small-cell lung cancer patients

Estimation of Cumulative Activity of 177 Lu-Cetuximab from a Single Diagnostic 64 Cu-Cetuximab Scan

Prognostic value of 18 F-FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project

Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with 18 F-fluoride

Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with 18F-Fluoride

On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma

6″- 18 F-Fluoromaltotriose PET Evaluation in Escherichia Coli -Induced Myositis: Is There Uptake Saturation in Control?

Could we avoid computing TMTV of DLBCL patients in routine practice?

Suchergebnisse filtern